SCHEMBL4765769

SCHEMBL4765769

CCN(CC)C1[C]Oc2ccccc21

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
USP2 O75604 1/20 0.39
SIGMAR1 Q99720 2/20 0.36
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALDH1A1 P00352 2/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31
CYP2C9 P11712 1/20 0.31
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
KCNE1 P15382 1/20 0.30
KCNQ1 P51787 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723614 0.92 MEN1 (0.41) MEN1KMT2AUSP2SIGMAR1TSHR
SCHEMBL4723731 0.89 KMT2A (0.36) MEN1KMT2AUSP2SIGMAR1TSHR
SCHEMBL4722732 0.86 MEN1 (0.42) MEN1KMT2AUSP2SIGMAR1TSHR
SCHEMBL4722635 0.84 MEN1 (0.38) MEN1KMT2AUSP2SIGMAR1TSHR
SCHEMBL4721713 0.83 KMT2A (0.37) MEN1KMT2AUSP2TSHRSMN1; SMN2
SCHEMBL4724712 0.83 MEN1 (0.37) MEN1KMT2AUSP2SIGMAR1TSHR
SCHEMBL4724912 0.81 KMT2A (0.38) MEN1KMT2ASIGMAR1TSHRSMN1; SMN2
SCHEMBL4723880 0.79 GPR3 (0.38) MEN1KMT2AUSP2SIGMAR1TSHR
SCHEMBL4723855 0.78 MEN1 (0.41) MEN1KMT2AUSP2SIGMAR1TSHR
SCHEMBL4723424 0.76 MEN1 (0.39) MEN1KMT2AUSP2SIGMAR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 MEN1 4451/4885KMT2A 3345/4885USP2 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.